Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study.

Abstract

To retrospectively investigate whether apical lesion, alveolar bone loss, probing pocket depth, or local infectious symptoms were associated with the onset of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with high-dose antiresorptive agents who did not undergo tooth extraction. The study included 92 patients receiving high-dose antiresorptive agent therapy who had teeth with apical lesion ≧ 3mm, alveolar bone loss ≧ 1/2, probing pocket depth ≧ 4mm, or local infection symptoms such as swelling, pain, and pus discharge, but did not undergo tooth extraction. Univariate and multivariate Cox regression analyses were performed to determine the relationship between each variable and MRONJ onset. MRONJ developed in 15 of 92 patients (35 of 404 teeth) from 74 to 1883days (median, 383days) after the first visit. Multiple Cox regression analysis revealed that a lower number of teeth, diabetes, increased leukocyte count, administration of antiresorptive agents for 180days or more, local infection symptoms, apical lesion ≧ 3mm, and probing pocket depth ≧ 4mm were significantly correlated with the development of MRONJ. It is recommended that teeth with apical lesion ≧ 3mm, probing pocket depth ≧ 4mm, or local infection symptoms are extracted before or as early as possible after beginning of medication in cancer patients receiving high-dose antiresorptive agent therapy to prevent the development of MRONJ.